FiercePharmaOriginal article
{"a":[{"_":"BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms","$":{"href":"/pharma/bms-ono-take-amgen-task-fdas-opdivo-biosimilar-decision-looms","hreflang":"en"}}]}
RegulatoryOpdivoNeutral
AI Analysis
Summary
Amgen is advancing its biosimilar application for Opdivo (nivolumab) as Bristol Myers Squibb and Ono Pharmaceutical work to defend their oncology blockbuster from competitive biosimilar entry.
Outcome Details
FDA decision on Amgen's Opdivo biosimilar application pending
Importance:7/10
Sentiment:
0.00
biosimilarFDAoncologyregulatoryOpdivocompetition
Read the original article
Published by FiercePharma on September 16, 2026 10:51 AM